PYRROLOPYRIMIDINE DERIVATIVE AS RSK INHIBITOR AND USE THEREOF

Title:

PYRROLOPYRIMIDINE DERIVATIVE AS RSK INHIBITOR AND USE THEREOF

Document Type and Number:

WIPO Patent Application WO/2024/056090

Kind Code:

A1

Abstract:

Disclosed are a pyrrolopyrimidine derivative as an RSK inhibitor and use thereof. Specifically, disclosed are a compound represented by formula I, a pharmaceutical composition containing the compound of formula I, and use of the compound in the preparation of a medicament for treating an RSK-related disease or inhibiting RSK.

More Like This:

JP2023552632	Novel compounds as dual androgen receptor and phosphodiesterase inhibitors
JP3780291	Tetrahydropyranyl cyclopentyl Tetrahydropyridpyridine-based chemokine receptor activity regulator
JP4409938	Azaindole

Inventors:

LI HONGLIN (CN)
LI SHILIANG (CN)
QIAN XUHONG (CN)
LIU KANGDONG (CN)
WANG ZHE (CN)
ZHAO ZHENJIANG (CN)
XU YUFANG (CN)
HE HUAN (CN)

Application Number:

PCT/CN2023/119236

Publication Date:

March 21, 2024

Filing Date:

September 15, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

UNIV EAST CHINA NORMAL (CN)
UNIV EAST CHINA SCIENCE & TECH (CN)
UNIV ZHENGZHOU (CN)
JINFENG LABORATORY (CN)

International Classes:

C07D519/00; A61K31/519; A61P35/00; C07D487/04

Domestic Patent References:

WO2007140222A2	2007-12-06
WO2016040848A1	2016-03-17

Foreign References:

CN105294737A

2016-02-03

Other References:

CASALVIERI, KIMBERLY A. ET AL.: "N-Substituted Pyrrolopyrimidines and Purines as p90 Ribosomal S6 Protein Kinase-2 (RSK2) Inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 41, 19 May 2021 (2021-05-19), XP086628688, DOI: 10.1016/j.bmc.2021.116220

Attorney, Agent or Firm:

XU & PARTNERS, LLC. (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: BASE STATION AND METHOD FOR SIMULTANEOUS TCI STATE UPDATE OPERATION

Next Patent: PYRIDONOPYRIMIDINE DERIVATIVE AS RSK INHIBITOR AND USE THEREOF